BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 28969629)

  • 1. Decision support systems for incurable non-small cell lung cancer: a systematic review.
    Révész D; Engelhardt EG; Tamminga JJ; Schramel FMNH; Onwuteaka-Philipsen BD; van de Garde EMW; Steyerberg EW; Jansma EP; De Vet HCW; Coupé VMH
    BMC Med Inform Decis Mak; 2017 Oct; 17(1):144. PubMed ID: 28969629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer.
    Révész D; Engelhardt EG; Tamminga JJ; Schramel FMNH; Onwuteaka-Philipsen BD; van de Garde EMW; Steyerberg EW; de Vet HCW; Coupé VMH
    J Cancer Educ; 2020 Apr; 35(2):345-351. PubMed ID: 30685832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Usefulness of Tools to Support Decision-making for Palliative Treatment of Metastatic Colorectal Cancer: A Systematic Review.
    Engelhardt EG; Révész D; Tamminga HJ; Punt CJA; Koopman M; Onwuteaka-Philipsen BD; Steyerberg EW; Jansma IP; De Vet HCW; Coupé VMH
    Clin Colorectal Cancer; 2018 Mar; 17(1):e1-e12. PubMed ID: 28734786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rapid learning in practice: a lung cancer survival decision support system in routine patient care data.
    Dekker A; Vinod S; Holloway L; Oberije C; George A; Goozee G; Delaney GP; Lambin P; Thwaites D
    Radiother Oncol; 2014 Oct; 113(1):47-53. PubMed ID: 25241994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
    Vickers AD; Winfree KB; Cuyun Carter G; Kiiskinen U; Jen MH; Stull D; Kaye JA; Carbone DP
    BMC Cancer; 2019 Apr; 19(1):353. PubMed ID: 30987609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology.
    J Clin Oncol; 1997 Aug; 15(8):2996-3018. PubMed ID: 9256144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).
    Sperduto PW; Yang TJ; Beal K; Pan H; Brown PD; Bangdiwala A; Shanley R; Yeh N; Gaspar LE; Braunstein S; Sneed P; Boyle J; Kirkpatrick JP; Mak KS; Shih HA; Engelman A; Roberge D; Arvold ND; Alexander B; Awad MM; Contessa J; Chiang V; Hardie J; Ma D; Lou E; Sperduto W; Mehta MP
    JAMA Oncol; 2017 Jun; 3(6):827-831. PubMed ID: 27892978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inventory of oncologists' unmet needs for tools to support decision-making about palliative treatment for metastatic colorectal cancer.
    Engelhardt EG; Révész D; Tamminga HJ; Punt CJA; Koopman M; Onwuteaka-Philipsen BD; Steyerberg EW; de Vet HCW; Coupé VMH
    BMC Med Inform Decis Mak; 2018 Dec; 18(1):132. PubMed ID: 30551735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).
    Chayab L; Konstantelos N; Leighl NB; Tadrous M; Wong WWL
    Pharmacoeconomics; 2023 Aug; 41(8):945-980. PubMed ID: 37268866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.
    Brule SY; Al-Baimani K; Jonker H; Zhang T; Nicholas G; Goss G; Laurie SA; Wheatley-Price P
    Lung Cancer; 2016 Jul; 97():15-21. PubMed ID: 27237022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and Validation of a Deep Learning Model for Non-Small Cell Lung Cancer Survival.
    She Y; Jin Z; Wu J; Deng J; Zhang L; Su H; Jiang G; Liu H; Xie D; Cao N; Ren Y; Chen C
    JAMA Netw Open; 2020 Jun; 3(6):e205842. PubMed ID: 32492161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer.
    Jackman DM; Zhang Y; Dalby C; Nguyen T; Nagle J; Lydon CA; Rabin MS; McNiff KK; Fraile B; Jacobson JO
    J Oncol Pract; 2017 Apr; 13(4):e346-e352. PubMed ID: 28260402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. External Validation of a Prognostic Score for Patients Receiving Palliative Thoracic Radiotherapy for Lung Cancer.
    Nieder C; Tollåli T; Haukland E; Reigstad A; Flatøy LR; Dalhaug A
    Clin Lung Cancer; 2017 Jul; 18(4):e297-e301. PubMed ID: 28189593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating Expected Costs and Benefits of Granting Access to New Treatments on the Basis of Progression-Free Survival in Non-Small-Cell Lung Cancer.
    Lakdawalla DN; Chou JW; Linthicum MT; MacEwan JP; Zhang J; Goldman DP
    JAMA Oncol; 2015 May; 1(2):196-202. PubMed ID: 26181023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.
    Ashworth A; Rodrigues G; Boldt G; Palma D
    Lung Cancer; 2013 Nov; 82(2):197-203. PubMed ID: 24051084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary therapeutic decision-making in inoperable non-small cell lung cancer.
    Erkurt E; Tunali C; Erkişi M
    Int J Radiat Oncol Biol Phys; 2000 Jan; 46(2):439-44. PubMed ID: 10661352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stage III non-small-cell lung cancer: Establishing a benchmark for the proportion of patients suitable for radical treatment.
    Al-Shamsi HO; Al Farsi A; Ellis PM
    Clin Lung Cancer; 2014 Jul; 15(4):274-80. PubMed ID: 24685356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical effectiveness and cost-effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation.
    Brown T; Pilkington G; Bagust A; Boland A; Oyee J; Tudur-Smith C; Blundell M; Lai M; Martin Saborido C; Greenhalgh J; Dundar Y; Dickson R
    Health Technol Assess; 2013 Jul; 17(31):1-278. PubMed ID: 23886301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinician perspectives on clinical decision support systems in lung cancer: Implications for shared decision-making.
    Ankolekar A; van der Heijden B; Dekker A; Roumen C; De Ruysscher D; Reymen B; Berlanga A; Oberije C; Fijten R
    Health Expect; 2022 Aug; 25(4):1342-1351. PubMed ID: 35535474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a National Comprehensive Cancer Network Guidelines-Based Decision Support Tool in Patients With Non-Small Cell Lung Cancer: A Nonrandomized Clinical Trial.
    Wu SY; Lazar AA; Gubens MA; Blakely CM; Gottschalk AR; Jablons DM; Jahan TM; Wang VEH; Dunbar TL; Wong ML; Chan JW; Guthrie W; Belkora J; Yom SS
    JAMA Netw Open; 2020 Sep; 3(9):e209750. PubMed ID: 32997124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.